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Combined Effect of Income and Medication Adherence on Mortality
in Newly Treated Hypertension: Nationwide Study of 16 Million
Person-Years
Hokyou Lee, MD; Jong Heon Park, MD, PhD; James S. Floyd, MD; Sungha Park, MD, PhD; Hyeon Chang Kim, MD, PhD
Background-—Low socioeconomic status and poor medication adherence are known to be associated with increased morbidity
and mortality among patients with hypertension, but their combined effects have not been studied. We therefore evaluated the
joint association of household income and medication adherence with death and cardiovascular disease in patients newly treated
for hypertension.
Methods and Results-—This was a nationwide cohort study using the Korean National Health Insurance database. We included
1 651 564 individuals, aged 30 to 80 years, with newly treated hypertension and no prior cardiovascular disease and followed
them for 10 years. Main exposures were household income in quintiles and adherence to antihypertensive medication, estimated
by medication possession ratio: good (≥0.8), moderate (0.5 to <0.8), or poor (<0.5). The primary outcomes were all-cause and
cardiovascular deaths. Higher mortality risk was observed in patients with low income (adjusted hazard ratio=1.50, 99% CI=
1.46-1.53; lowest versus highest quintile) and poor medication adherence (adjusted hazard ratio=1.66, 99% CI=1.63-1.68; poor
versus good adherence). When compared with the highest-income and good-adherence group, adjusted hazard ratio (99% CI) of
death was 1.56 (1.52-1.61) for highest-income poor-adherers, 1.46 (1.41-1.51) for lowest-income good-adherers, and 2.46
(2.38-2.54) for lowest-income poor-adherers (P for interaction <0.001).
Conclusions-—Low socioeconomic status and poor adherence to antihypertensive medication are associated with increased
mortality and cardiovascular disease risks, but patients with low income are subject to larger excess risks by nonadherence. This
highlights the potential importance of promoting medication adherence for risk reduction, especially in low-income patients with
hypertension. ( J Am Heart Assoc. 2019;8:e013148. DOI: 10.1161/JAHA.119.013148.)
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H igh blood pressure is the leading risk factor for deathand cardiovascular disease (CVD) globally.1 Despite
effective blood pressure-lowering treatments available,
populations of low socioeconomic status often have poor
awareness and control.2-4 Accruing evidence suggests
that socioeconomic deprivation is associated with increased
risk for death and CVD.5 However, among patients newly
treated for hypertension, there are scarce data on mortality
according to income gradient or on which factors can
be improved to lower poverty-related death in these
patients.
Previous studies have reported an association between
adherence to antihypertensive medication and cardiovascular
events.6,7 Medication adherence is an important clinical and
public health issue, given that nonadherence is a major risk
factor for adverse outcome and increased medical cost.8
Although nonadherence is prevalent among low-income
patients, it is unclear whether its effect on clinical outcome
varies according to socioeconomic gradient because the
combined effect of income and medication adherence has not
been fully studied. Therefore, in a large primary prevention
population, we investigated the risks for death and CVD
hospitalizations according to combination of household
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income and medication adherence in patients who started
hypertension treatment.
Methods
Because of the sensitive nature of the data collected for this
study, requests to access the data set from qualiﬁed researchers
may be sent to the National Health Insurance Service (NHIS) at
https://nhiss.nhis.or.kr/bd/ab/bdaba000eng.do
Data Source
We used a nationwide electronic database provided by the
NHIS, which includes deidentiﬁed claim records of the entire
Korean population. The NHIS is the single provider of
universal healthcare coverage in South Korea. The NHIS
database encompasses both insurance programs: health
insurance program covering 97% of the population, and
medical aid program covering the remaining 3% with ﬁnancial
needs or under special provisions (eg, national meritorious
individuals). The database contains sociodemographic details,
reimbursement claims with International Classiﬁcation of
Disease, Tenth Edition (ICD-10) coding, general health
checkup results, and death information.9 Description of the
data source has been done in previous studies.10 The study
protocol was approved by the Institutional Review Board of
Severance Hospital, Yonsei University Health System, Seoul,
Korea (Approval No. 4-2017-0322). Informed consent was not
required, as this is a retrospective study of deidentiﬁed
administrative data.
Study Population
We identiﬁed 1 977 432 individuals, aged 30 to 80, newly
treated for primary hypertension (ICD-10 code I10 with
antihypertensive medication; Table S1) from January 1,
2004 to December 31, 2007. Identiﬁcation of treated
hypertension followed the protocol developed by the Korean
Society of Hypertension.10,11 We excluded patients with
prior diagnosis or medication for any hypertensive disease,
prior myocardial infarction (MI), heart failure, or stroke
(Table S2), or fewer than 2 prescriptions during the ﬁrst
year of treatment (Figure S1). To minimize the effect of
reverse causality, we also excluded individuals who died or
had a CVD event within 2 years following the index date
(N=88 830). Those with incomplete income information,
including medical aid beneﬁciaries, were also omitted from
the analysis (N=237 038). The ﬁnal 1 651 564 individuals
were followed until death, migration from the database, or
censoring date (10 years from the index date), whichever
came ﬁrst.
Sociodemographic Information and Covariates
As a proxy for household income we used insurance
premium, determined by government assessment of salary
and assets, rather than self-report. Household insurance
premiums were grouped into quintiles among all households
in Korea at the index year. Medical aid beneﬁciaries do not
pay insurance premiums; their economic statuses are
heterogeneous and are not included in the income quintiles.
We therefore excluded medical aid from the study. Working
status was categorized into either employed or self-/
unemployed. The Charlson Comorbidity Index was calculated
using ICD-10 codes12,13 claimed during the 2 years before
the index date.
Assessment of Medication Adherence
Antihypertensive adherence was determined by medication
possession ratio, which is the number of days’ medication
supplied divided by the number of days in a time period.14 The
medication possession ratio is among the best available
methods using retrospective data15 and correlates well with
other adherence measures.16 We calculated the medication
possession ratio for the ﬁrst 2 years after index date and
classiﬁed it into 3 levels: good (≥0.8), moderate (≥0.5 and
<0.8), or poor (<0.5) adherence, as done in previous
studies.7,17,18 We capped the medication possession ratio at
1.0 to discard days oversupplied.
Clinical Perspective
What Is New?
• Both low income and poor medication adherence are
associated with higher mortality, but their joint association
is more potent than each risk factor individually.
• The excess risk by poor medication adherence is greater in
individuals with low socioeconomic status, but even with
good medication adherence, low-income patients are still at
increased mortality risk.
What Are the Clinical Implications?
• Measures to improve medication adherence should be
sought to reduce mortality in low-income patients with
hypertension, and management of poverty-driven cardiovas-
cular risk factors should accompany these measures.
• Because socioeconomic information is readily available from
existing data, future research may identify uniquely vulner-
able patients for evidence-based interventions to optimize
pharmacologic therapy and improve medication adherence.
DOI: 10.1161/JAHA.119.013148 Journal of the American Heart Association 2
Income, Adherence, and Mortality in Hypertension Lee et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Outcomes
The primary outcomes were all-cause and cardiovascular
deaths. All deaths and their causes were ascertained by
linkage to the Statistics Korea database via resident registra-
tion numbers. Cardiovascular death was deﬁned as death due
to CVD (ICD-10, I00-I99) by certiﬁcate. The secondary
outcomes were atherosclerotic CVD, a composite of MI
and/or stroke, MI, stroke, and heart failure, deﬁned as the
ﬁrst hospitalization with the corresponding condition as the
main diagnosis (Table S2).
Statistical Analyses
Baseline characteristics were reported as frequency and
percentage or median and interquartile range. We used a Cox
proportional hazards model to calculate hazard ratio (HR) and
99% CI for each outcome according to household income,
medication adherence, and the combination of the 2 (15
levels: 5 levels of income by 3 levels of adherence).
Multivariable Cox regression was adjusted for age, sex,
employment status, household income, Charlson Comorbidity
Index, use of glucose-lowering drugs, use of lipid-lowering
drugs, antihypertensive drug class, and medication adher-
ence. We further stratiﬁed our analyses by sex, given that
health-related behaviors, medication adherence, and mortality
may differ by sex. Interactions of sex with income and
adherence and interaction between the income and adher-
ence interaction within each sex were tested as continuous
terms in the full model. The proportionality of hazards was
checked graphically by log-minus-log plot and by Schoenfeld
residuals. The assumption of proportional hazards was not
violated.
Several additional analyses were done on different subsets
or inclusion of data. First, monotherapy initiators
(N=923 664, excluding ﬁrst-line b-blockers) and combination
therapy initiators (N=572 445) were analyzed separately.
Second, given our operational deﬁnition excluding individuals
with only 1 prescribing visit for stricter identiﬁcation of
treated hypertension, we performed sensitivity analyses
including those without further visits (total N=2 163 335) to
ensure that excluding these individuals did not alter the
association between adherence and mortality. Finally,
because our main analysis did not account for lifestyle or
clinical parameters, we performed additional analyses on
643 026 individuals with health checkup results closest to,
and within the past 2 years from, the index date (median
7.3 months). We added cigarette smoking (never, past, or
current), alcohol consumption (none, 1-2 times/wk, ≥3 times/
wk), physical exercise (none, 1-2 times/wk, ≥3 times/wk),
body mass index, systolic blood pressure, fasting glucose, and
total cholesterol in this model. Details of health screening
variables are described elsewhere.19 All analyses were
performed using SAS version 9.4 (SAS Institute Inc, Cary,
NC) and R version 3.4.4 (R Foundation for Statistical
Computing, Vienna, Austria) with survival package.
Results
Baseline Characteristics
A total of 1 651 564 individuals were followed for
15 956 805 person-years. Baseline characteristics by income
levels are summarized in Table 1. Median age was 53
(interquartile range 46-63) years, and 47.5% were women.
Age was comparable across income levels, and female sex
and employed status were more prevalent in the lowest
income group. Individuals with lower income were more
likely to be on multiple antihypertensive agents. For the
initial regimen, diuretics, beta-blockers, or calcium channel
blockers were more common in lower income groups,
whereas angiotensin II receptor blockers were more fre-
quently used in higher income groups. Distribution of
Charlson Comorbidity Index was comparable across the
groups, but patients with lower income had marginally fewer
documented comorbidities.
During the ﬁrst 2 years of treatment, 742 387 (45.0%)
patients showed good adherence, 348 236 (21.1%) moderate
adherence, and 560 941 (34.0%) poor adherence to antihy-
pertensive medication. Medication adherence tended to be
positively associated with household income. Further descrip-
tive statistics stratiﬁed by level of adherence are summarized
in Table S3.
Death and CVD Hospitalizations According to
Income and Medication Adherence
During 15 956 805 person-years, 136 287 deaths were
observed. Mortality rates were higher in individuals with
lower household income (1010.9 versus 779.1 per
100 000 person-years; lowest versus highest income).
Lower household income was independently associated with
increased mortality, even after adjustment for age, sex,
employment, comorbidities, antihypertensive medications,
and adherence. The HR (99% CI) for all-cause and cardio-
vascular death were 1.64 (1.59-1.68) and 1.75 (1.64-1.87)
in men and 1.31 (1.27-1.36) and 1.38 (1.29-1.47) in women,
when lowest-income group was compared with highest-
income group (Table 2). Poor medication adherence was
also associated with greater risk for all-cause and cardio-
vascular death—HR (99% CI), 1.70 (1.66-1.73) and 1.95
(1.86-2.05) in men and 1.56 (1.52-1.60) and 1.74 (1.64-
1.83) in women—when compared with good adherence
and adjusted for covariates (Table 2). There were signiﬁcant
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interactions of sex with both income and adherence in
association with all outcomes (P<0.005) except for myocar-
dial infarction (P>0.1).
When stratiﬁed by the combination of income and
adherence, poor medication adherence was associated with
higher risk for all-cause and cardiovascular death across all
income groups. However, the absolute risks and their
difference by adherence gradually increased toward lower
household income, especially in men. In lowest-income men,
cumulative death rates were 1714.7 versus 1064.8 per
100 000 person-years for poor versus good adherers,
whereas in highest-income men, rates were 1110.1 versus
694.9 per 100 000 person-years for poor versus good
adherers. After adjustment for covariates, excess risk for
all-cause death associated with poor medication adherence
was 117% in lowest-income men and 59% in highest-income
Table 1. Baseline Characteristics by Household Income
Household Income, Quintile
Q5, Highest Q4 Q3 Q2 Q1, Lowest
(N=470 609) (N=371 434) (N=297 474) (N=240 613) (N=271 434)
Age, y 54 [46-64] 53 [45-63] 53 [45-61] 53 [46-61] 55 [47-63]
Sex
Female 212 709 (45.2%) 170 661 (45.9%) 137 849 (46.3%) 117 620 (48.9%) 145 660 (53.7%)
Male 257 900 (54.8%) 200 773 (54.1%) 159 625 (53.7%) 122 993 (51.1%) 125 774 (46.3%)
Employment status
Employed workers 107 543 (22.9%) 69 086 (18.6%) 56 082 (18.9%) 49 733 (20.7%) 93 535 (34.5%)
Self- or unemployed 363 066 (77.1%) 302 348 (81.4%) 241 392 (81.1%) 190 880 (79.3%) 177 899 (65.5%)
Initial antihypertensive agent*
Diuretics 123 885 (26.3%) 102 736 (27.7%) 84 339 (28.4%) 69 269 (28.8%) 78 558 (28.9%)
b-blockers 99 990 (21.2%) 81 707 (22.0%) 66 773 (22.4%) 54 863 (22.8%) 61 236 (22.6%)
Calcium channel blockers 262 915 (55.9%) 215 554 (58.0%) 175 943 (59.1%) 144 130 (59.9%) 163 669 (60.3%)
ACE inhibitors 58 650 (12.5%) 47 909 (12.9%) 38 161 (12.8%) 30 340 (12.6%) 34 068 (12.6%)
Angiotensin II receptor blockers 112 559 (23.9%) 78 138 (21.0%) 60 241 (20.3%) 46 758 (19.4%) 51 299 (18.9%)
Others 3643 (0.8%) 2589 (0.7%) 2004 (0.7%) 1610 (0.7%) 1818 (0.7%)
Number of antihypertensive class
1 314 312 (66.8%) 243 264 (65.5%) 192 307 (64.6%) 154 550 (64.2%) 174 686 (64.4%)
2 125 283 (26.6%) 102 261 (27.5%) 83 115 (27.9%) 68 000 (28.3%) 76 719 (28.3%)
≥3 31 014 (6.6%) 25 909 (7.0%) 22 052 (7.4%) 18 063 (7.5%) 20 029 (7.4%)
Use of glucose-lowering drugs 79 180 (16.8%) 64 529 (17.4%) 52 405 (17.6%) 42 794 (17.8%) 48 045 (17.7%)
Use of lipid-lowering drugs 66 642 (14.2%) 47 198 (12.7%) 35 768 (12.0%) 27 490 (11.4%) 30 420 (11.2%)
Charlson Comorbidity Index
0 231 950 (49.3%) 185 006 (49.8%) 151 885 (51.1%) 124 890 (51.9%) 142 041 (52.3%)
1 89 736 (19.1%) 71 188 (19.2%) 55 936 (18.8%) 45 156 (18.8%) 53 196 (19.6%)
2 81 841 (17.4%) 63 871 (17.2%) 50 237 (16.9%) 39 405 (16.4%) 42 729 (15.7%)
≥3 67 082 (14.3%) 51 369 (13.8%) 39 416 (13.3%) 31 162 (13.0%) 33 468 (12.3%)
Medication possession ratio 0.78 [0.37-0.95] 0.75 [0.32-0.94] 0.72 [0.29-0.93] 0.71 [0.27-0.92] 0.73 [0.30-0.93]
Medication adherence
Good 225 169 (47.8%) 167 883 (45.2%) 128 731 (43.3%) 101 928 (42.4%) 118 676 (43.7%)
Moderate 97 682 (20.8%) 78 119 (21.0%) 63 202 (21.2%) 51 511 (21.4%) 57 722 (21.3%)
Poor 147 758 (31.4%) 125 432 (33.8%) 105 541 (35.5%) 87 174 (36.2%) 95 036 (35.0%)
Data are presented as median [interquartile range] or frequency (percent). ACE indicates angiotensin-converting-enzyme.
*Counted with duplicates for combination therapy.
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men (Figure 1). Similarly, excess risks for cardiovascular
death associated with poor adherence were 178% versus 84%
in lowest- versus highest-income men, respectively (Figure 1).
There were signiﬁcant interactions between income and
adherence in association with all-cause and cardiovascular
death (P<0.001 and 0.020). In women, the difference in
mortality risk by income was also present but was not as
prominent as in men. Excess risks associated with poor
Table 2. All-Cause and Cardiovascular Death According to Household Income and Medication Adherence
Variables People
All-Cause Death Cardiovascular Death
Events Rate*
HR (95% CI)
Events Rate*
HR (95% CI)
Model 1 Model 2 Model 1 Model 2
Total 1 651 564 136 287 854.1 27 195 170.4
Income, quintile
5, highest 470 609 35 544 779.1 1.00 (reference) 1.00 (reference) 6974 152.9 1.00 (reference) 1.00 (reference)
4 371 434 29 156 810.5 1.16 (1.13-1.18) 1.14 (1.12-1.17) 5838 162.3 1.21 (1.16-1.27) 1.19 (1.13-1.24)
3 297 474 23 888 831.0 1.29 (1.26-1.32) 1.26 (1.23-1.29) 4681 162.8 1.34 (1.27-1.40) 1.29 (1.23-1.35)
2 240 613 21 365 921.7 1.46 (1.42-1.49) 1.41 (1.38-1.44) 4274 184.4 1.53 (1.46-1.61) 1.46 (1.39-1.54)
1, lowest 271 434 26 334 1010.9 1.54 (1.51-1.58) 1.50 (1.46-1.53) 5428 208.4 1.63 (1.56-1.71) 1.55 (1.48-1.63)
Adherence
Good 742 387 49 451 683.6 1.00 (reference) 1.00 (reference) 9374 129.6 1.00 (reference) 1.00 (reference)
Moderate 348 236 29 140 866.5 1.35 (1.32-1.37) 1.30 (1.28-1.33) 5883 174.9 1.43 (1.37-1.49) 1.41 (1.35-1.47)
Poor 560 941 57 696 1076.4 1.70 (1.67-1.73) 1.66 (1.63-1.68) 11 938 222.7 1.84 (1.78-1.91) 1.88 (1.81-1.95)
Men 867 065 85 811 1032.1 15 198 182.8
Income, quintile
5, highest 257 900 21 290 854.9 1.00 (reference) 1.00 (reference) 3589 144.1 1.00 (reference) 1.00 (reference)
4 200 773 18 669 966.7 1.20 (1.17-1.23) 1.18 (1.15-1.21) 3353 173.6 1.29 (1.21-1.37) 1.26 (1.18-1.34)
3 159 625 15 624 1020.7 1.35 (1.31-1.38) 1.31 (1.27-1.34) 2743 179.2 1.42 (1.33-1.52) 1.36 (1.27-1.45)
2 122 993 14 139 1207.0 1.58 (1.54-1.63) 1.53 (1.48-1.57) 2589 221.0 1.75 (1.63-1.87) 1.65 (1.54-1.76)
1, lowest 125 774 16 089 1351.4 1.70 (1.66-1.75) 1.64 (1.59-1.68) 2924 245.6 1.87 (1.75-1.99) 1.75 (1.64-1.87)
Adherence
Good 389 003 30 735 815.2 1.00 (reference) 1.00 (reference) 5191 137.7 1.00 (reference) 1.00 (reference)
Moderate 180 554 17 823 1029.5 1.36 (1.33-1.40) 1.31 (1.28-1.34) 3139 181.3 1.43 (1.35-1.51) 1.40 (1.32-1.49)
Poor 297 508 37 253 1324.4 1.77 (1.73-1.80) 1.70 (1.66-1.73) 6868 244.2 1.93 (1.84-2.02) 1.95 (1.86-2.05)
Women 784 499 50 476 660.5 11 997 157.0
Income, quintile
5, highest 212 709 14 254 688.0 1.00 (reference) 1.00 (reference) 3385 163.4 1.00 (reference) 1.00 (reference)
4 170 661 10 487 629.5 1.10 (1.07-1.14) 1.10 (1.06-1.13) 2485 149.2 1.15 (1.07-1.23) 1.13 (1.05-1.21)
3 137 849 8264 615.0 1.21 (1.17-1.25) 1.19 (1.15-1.24) 1938 144.2 1.26 (1.17-1.36) 1.23 (1.14-1.32)
2 117 620 7226 630.2 1.27 (1.22-1.32) 1.24 (1.20-1.29) 1685 147.0 1.31 (1.22-1.42) 1.26 (1.17-1.37)
1, lowest 145 660 10 245 724.3 1.34 (1.30-1.39) 1.31 (1.27-1.36) 2504 177.0 1.44 (1.34-1.54) 1.38 (1.29-1.47)
Adherence
Good 353 384 18 716 540.3 1.00 (reference) 1.00 (reference) 4183 120.8 1.00 (reference) 1.00 (reference)
Moderate 167 682 11 317 693.6 1.30 (1.26-1.34) 1.27 (1.24-1.31) 2744 168.2 1.39 (1.31-1.48) 1.38 (1.30-1.47)
Poor 263 433 20 443 802.6 1.57 (1.53-1.61) 1.56 (1.52-1.60) 5070 199.1 1.70 (1.61-1.80) 1.74 (1.64-1.83)
Model 1 included either income or adherence as the primary independent variable and was adjusted for age, sex, and employment status. Model 2 included both income and adherence as
independent variables and was adjusted for age, sex, employment status, Charlson Comorbidity Index, use of glucose-lowering drugs, use of lipid-lowering drugs, and antihypertensive drug
class. HR indicates hazard ratio.
*Per 100 000 person-years.
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adherence in lowest- versus highest-income women were 73%
versus 52% for all-cause death and 102% versus 58% for
cardiovascular death (Figure 1). Income-adherence interac-
tion did not reach statistical signiﬁcance in women (P>0.1).
Kaplan-Meier curves for all-cause and cardiovascular death
showed that both income and adherence were individually
associated with survival, but the impact of low income on
survival was much less in women than in men (Figure 2).
Associations with CVD hospitalizations showed similar joint
effects of income and adherence, but interactions between
income and adherence did not reach statistical signiﬁcance
for nonfatal outcomes (P>0.1) except for stroke in women
(Figures S2, S3, and Tables S4, S5).
Additional Analyses
We performed several additional analyses on different
subsets or inclusion criteria. First, when monotherapy and
combination therapy initiators were analyzed separately, the
income-adherence joint associations with mortality and its
sex difference were consistently observed in both groups
(Figures S4 and S5). Second, when patients with fewer than
2 visits were added as sensitivity analyses, the HRs were
marginally attenuated, but the joint income-adherence
associations with mortality and the sex difference remained
(Figure S6). Finally, we performed an additional analysis on
643 026 individuals with health examination results. Overall
mortality rates in health examinees were lower than in the
entire study patients (685.3 per 100 000 person-years). We
observed consistent joint associations of income and
adherence with death and CVD, as described in the main
analysis, but with attenuated HRs when further adjustment
was made for cigarette smoking, alcohol consumption,
physical exercise, body mass index, systolic blood pressure,
fasting glucose, and total cholesterol (Figure 3 and Tables
S6 and S7). Income-adherence interaction did not reach
Men All-cause death Cardiovascular death
Income Adherence Patients Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 126,148 8,530 694.9 1.00 (reference) 1,356 110.5 1.00 (reference)
Moderate 53,094 4,430 864.6 1.29 (1.23-1.36) 777 151.6 1.47 (1.31-1.65)
Poor 78,658 8,330 1110.1 1.59 (1.52-1.65) 1,456 194.0 1.84 (1.67-2.03)
4 Good 90,474 6,830 777.6 1.14 (1.10-1.19) 1,181 134.5 1.25 (1.12-1.38)
Moderate 41,733 3,874 965.6 1.50 (1.43-1.58) 712 177.5 1.80 (1.59-2.03)
Poor 68,566 7,965 1222.1 1.94 (1.86-2.02) 1,460 224.0 2.36 (2.14-2.61)
3 Good 67,773 5,261 800.9 1.24 (1.18-1.30) 911 138.7 1.35 (1.21-1.51)
Moderate 33,791 3,310 1021.6 1.68 (1.60-1.78) 564 174.1 1.86 (1.64-2.12)
Poor 58,061 7,053 1282.6 2.18 (2.09-2.27) 1,268 230.6 2.61 (2.36-2.89)
2 Good 50,833 4,613 939.9 1.45 (1.38-1.52) 785 160.0 1.55 (1.38-1.75)
Moderate 25,825 2,933 1191.4 1.93 (1.82-2.04) 535 217.3 2.27 (1.99-2.59)
Poor 46,335 6,593 1517.7 2.56 (2.45-2.67) 1,269 292.1 3.27 (2.95-3.62)
1, lowest Good 53,775 5,501 1064.8 1.58 (1.51-1.66) 958 185.4 1.73 (1.55-1.93)
Moderate 26,111 3,276 1323.7 2.02 (1.92-2.13) 551 222.6 2.19 (1.92-2.50)
Poor 45,888 7,312 1714.7 2.75 (2.64-2.86) 1,415 331.8 3.51 (3.18-3.88)
Women All-cause death Cardiovascular death
Income Adherence Patients Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 99,021 5,597 577.3 1.00 (reference) 1,295 133.6 1.00 (reference)
Moderate 44,588 3,174 731.8 1.28 (1.21-1.36) 787 181.5 1.37 (1.22-1.54)
Poor 69,100 5,483 820.0 1.52 (1.45-1.60) 1,303 194.9 1.58 (1.43-1.75)
4 Good 77,409 3,900 513.1 1.08 (1.02-1.13) 843 110.9 1.04 (0.93-1.17)
Moderate 36,386 2,387 673.3 1.42 (1.33-1.51) 583 164.4 1.55 (1.36-1.76)
Poor 56,866 4,200 761.8 1.69 (1.60-1.78) 1,059 192.1 1.92 (1.73-2.14)
3 Good 60,958 3,040 508.7 1.18 (1.11-1.25) 654 109.4 1.15 (1.01-1.30)
Moderate 29,411 1,752 611.2 1.44 (1.34-1.54) 413 144.1 1.53 (1.33-1.78)
Poor 47,480 3,472 755.6 1.90 (1.79-2.01) 871 189.5 2.17 (1.94-2.43)
2 Good 51,095 2,552 509.2 1.23 (1.16-1.31) 571 113.9 1.24 (1.09-1.41)
Moderate 25,686 1,699 679.5 1.60 (1.49-1.71) 399 159.6 1.69 (1.46-1.96)
Poor 40,839 2,975 752.4 1.91 (1.80-2.02) 715 180.8 2.08 (1.84-2.34)
1, lowest Good 64,901 3,627 570.8 1.31 (1.24-1.38) 820 129.0 1.32 (1.18-1.49)
Moderate 31,611 2,305 751.5 1.64 (1.53-1.74) 562 183.2 1.77 (1.55-2.01)
Poor 49,148 4,313 913.3 2.04 (1.94-2.15) 1,122 237.6 2.34 (2.11-2.61)
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
0.5 1.0 1.5 2.0 2.5 3.0
0.5 1.0 1.5 2.0 2.5 3.0
Figure 1. Combined effect of income and adherence on all-cause and cardiovascular death in men and women. Multivariate Cox regression
adjusted for age, employment status, Charlson Comorbidity Index, use of glucose-lowering drugs, use of lipid-lowering drugs, and
antihypertensive drug class. P for interaction between income and adherence in men and women was <0.001 and 0.454 for all-cause death and
0.020 and 0.187 for cardiovascular death, respectively. HR indicates hazard ratio. *Per 100 000 person-years.
DOI: 10.1161/JAHA.119.013148 Journal of the American Heart Association 6
Income, Adherence, and Mortality in Hypertension Lee et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
statistical signiﬁcance in this analysis. A fraction of these
participants underwent a repeated examination within 2 to
4 years after index date (median 2.8 years, N=466 103).
On follow-up, individuals with poor medication adherence
had smaller blood pressure reduction than those with good
adherence (Figure S7). This trend was comparable across
all income groups and after adjustment for baseline systolic
blood pressure and other risk factors.
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Figure 2. Kaplan-Meier curves for all-cause and cardiovascular death stratiﬁed by income and adherence in men and women. *Income was
dichotomized into high (upper 50%) and low (lower 50%).
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Discussion
In this nationwide study of newly treated hypertension, we
found that low income and poor adherence to antihyperten-
sive medication were associated with increased mortality, and
the excess risk by poor adherence was greater in individuals
with low socioeconomic status. People with lower household
income were not only more likely to be nonadherent but were
also at higher risk for death when they were not adherent to
antihypertensive medication. From this excess risk from poor
versus good medication adherence in our study, we project an
absolute risk reduction over 500 per 100 000 person-years
for an intervention that would promote medication adherence
in the lowest income group, assuming causality between
nonadherence and mortality. Of note, Koreans have a high
rate of healthcare utilization due to universal health insurance
coverage, as evident by the largest number of doctor visits per
capita among Organisation for Economic Cooperation and
Development countries,20 and a high participation rate in the
national general health screening program (eg, 77.7% in
2016).21 Therefore, the ﬁnding of a signiﬁcant differential
income effect under such a highly accessible healthcare
system is unexpected and noteworthy.
Socioeconomic status has long been implicated as a major
risk factor for death and CVD.22 Low-income countries as well
as low-income subpopulations within developed countries
have higher CVD prevalence and mortality rates.23 However,
there is limited evidence of which modiﬁable risk factor
should be targeted for intervention in low-income patients
with hypertension. Previous studies have reported that poor
All-cause death Model 1 Model 2
Income Adherence Patients Events Rate* HR (99% CI)     Low risk     High risk HR (99% CI)     Low risk     High risk
5, highest Good 99,188 4,747 487.2 1.00 (reference) 1.00 (reference)
Moderate 40,270 2,392 608.5 1.31 (1.23-1.40) 1.27 (1.19-1.36)
Poor 58,287 4,162 735.3 1.51 (1.43-1.60) 1.45 (1.37-1.53)
4 Good 69,541 3,643 534.1 1.18 (1.11-1.25) 1.14 (1.08-1.21)
Moderate 29,922 1,863 638.3 1.48 (1.38-1.59) 1.40 (1.30-1.50)
Poor 46,905 3,602 792.4 1.82 (1.72-1.93) 1.67 (1.58-1.77)
3 Good 49,969 2,692 549.7 1.22 (1.15-1.30) 1.16 (1.09-1.23)
Moderate 22,631 1,571 714.0 1.66 (1.54-1.78) 1.52 (1.41-1.64)
Poor 36,460 3,138 892.4 2.10 (1.98-2.23) 1.90 (1.78-2.01)
2 Good 39,344 2,445 636.1 1.41 (1.33-1.51) 1.31 (1.23-1.40)
Moderate 17,886 1,474 851.4 1.87 (1.73-2.02) 1.70 (1.57-1.83)
Poor 28,462 2,779 1017.9 2.20 (2.07-2.34) 1.94 (1.82-2.06)
1, lowest Good 50,190 3,308 675.3 1.47 (1.38-1.56) 1.37 (1.29-1.45)
Moderate 21,538 1,710 819.1 1.78 (1.65-1.91) 1.60 (1.49-1.72)
Poor 32,433 3,392 1093.6 2.31 (2.18-2.45) 2.04 (1.92-2.16)
Cardiovascular death Model 1 Model 2
Income Adherence Patients Events Rate* HR (99% CI)     Low risk     High risk HR (99% CI)     Low risk     High risk
5, highest Good 99,188 820 84.2 1.00 (reference) 1.00 (reference)
Moderate 40,270 427 108.6 1.38 (1.18-1.61) 1.34 (1.15-1.56)
Poor 58,287 776 137.1 1.69 (1.48-1.92) 1.64 (1.44-1.87)
4 Good 69,541 622 91.2 1.18 (1.03-1.36) 1.14 (0.99-1.31)
Moderate 29,922 364 124.7 1.73 (1.47-2.03) 1.63 (1.38-1.91)
Poor 46,905 675 148.5 2.09 (1.82-2.39) 1.94 (1.69-2.22)
3 Good 49,969 459 93.7 1.22 (1.05-1.42) 1.15 (0.99-1.34)
Moderate 22,631 301 136.8 1.90 (1.59-2.26) 1.73 (1.45-2.06)
Poor 36,460 583 165.8 2.39 (2.08-2.76) 2.17 (1.89-2.50)
2 Good 39,344 401 104.3 1.35 (1.15-1.58) 1.24 (1.06-1.45)
Moderate 17,886 281 162.3 2.08 (1.74-2.49) 1.88 (1.57-2.25)
Poor 28,462 545 199.6 2.60 (2.25-3.00) 2.31 (2.00-2.67)
1, lowest Good 50,190 575 117.4 1.46 (1.26-1.68) 1.34 (1.16-1.55)
Moderate 21,538 330 158.1 1.96 (1.65-2.32) 1.75 (1.48-2.08)
Poor 32,433 666 214.7 2.68 (2.34-3.07) 2.38 (2.07-2.72)
0.5 1.0 1.5 2.0 2.5 0.5 1.0 1.5 2.0 2.5
0.5 1.0 1.5 2.0 2.5 3.0 3.5 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Figure 3. Combined effect of income and adherence on all-cause and cardiovascular death in health examinees. Multivariate Cox regression
with model 1 adjusted for age, sex, employment status, Charlson Comorbidity Index, use of glucose-lowering drugs, use of lipid-lowering drugs,
and antihypertensive drug class; model 2 further adjusted for cigarette smoking, alcohol consumption, physical exercise, body mass index,
systolic blood pressure, fasting glucose, and total cholesterol. P for interaction between income and adherence in model 1 and model 2 was
0.173 and 0.385 for all-cause death and 0.144 and 0.192 for cardiovascular death, respectively. HR indicates hazard ratio. *Per
100 000 person-years.
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medication adherence is associated with morbidity and
mortality in individuals with hypertension.6,7 Our ﬁndings
suggest that low income and medication nonadherence are
important risk factors for mortality and CVD among initiators
of hypertension treatment, and the joint association of
income and adherence appears to be even more potent than
each risk factor individually. Because these measures are
readily available from existing data, it may be possible to
identify uniquely vulnerable patients for evidence-based
interventions that seek to optimize pharmacologic therapy
and to improve medication adherence.
Determinants of medication adherence may be multifac-
torial, including demographics, comorbidities, and socioeco-
nomic status.24 In our study good medication adherence
was associated with older age, female sex, higher income,
employed status, concurrent uses of glucose-lowering and
lipid-lowering drugs, and single-pill combination antihyperten-
sive therapy, although further study is needed because only a
limited number of predictors could be assessed. Use of single-
pill combinations may promote adherence and reduce cost
simultaneously.17,25 Optimal visit schedules or follow-up
strategies to maximize adherence in low-income patients
should be further studied, and policies should tackle socioe-
conomic barriers to healthcare access in patients with low
income or other social deprivations.
There are several explanations how nonadherence-related
adverse outcome could be affected by income gradient.
Despite universal health insurance coverage in Korea, relative
poverty and its implication in health disparity require atten-
tion.26 In the KNHANES (Korean National Health and Nutrition
Examination Survey), patients with low income were more
likely to experience unmet healthcare needs and to have
uncontrolled hypertension or comorbidities.27,28 Limited
access to healthcare services in a low-income population
may lead to more masked or undocumented comorbidities.29
Clinical severity and unhealthy lifestyle are also associated
with low socioeconomic status and, in turn, with adverse
outcome.30 A high proportion of low-income patients in our
study were prescribed 3 or more antihypertensive agents,
reﬂecting greater likelihood of their having severe or uncon-
trolled hypertension. Furthermore, prevalence of other meta-
bolic abnormalities may also be higher in low-income
individuals.31 In our additional analysis with adjustments for
smoking, drinking, exercise, body mass index, systolic blood
pressure, fasting glucose, and total cholesterol, the joint
association of income and adherence with mortality was
attenuated but still remained. Moreover, residual risk by low
income in good medication adherers is still unexplained after
full adjustments. Therefore, further study is needed on some
other contributing factors. Notably, Koreans have higher
sodium consumption (4.5 g/d) than global average or WHO
recommendations, and sodium intake is even higher in
individuals with low socioeconomic status or with other poor
health behaviors.32 Job strain is another important risk factor
for higher prevalence and worse control of hypertension
associated with low socioeconomic status.33 Although we did
not specify job types, we observed higher proportions of
employed workers in lower income groups, where job strain
may have contributed to difﬁcult blood pressure control and
worse cardiovascular outcome.
The reason for sex difference in poverty-related mortality
in our study is not clear. Because overall mortality rate and
cardiovascular risk are much lower in women, the impact of
socioeconomic status may not be as conspicuous as in men.
In our study, medication adherence was marginally higher,
and the difference by income was smaller, in women than in
men. This is in line with another study reporting higher
health literacy in women and smaller gradient of health
literacy by income in women compared with men.34 Differ-
ences in social and occupational positions by sex may also
provide some explanations. Fewer than 10% of women in our
study were employed workers, and conversely, the vast
majority of women were dependent family members who
may have had less exposure to work-related risk factors and
better access to healthcare services, compared with
employed workers. Moreover, household income may have
a weaker association with health-related behaviors in family
dependents, whose individual economic status are not
directly represented. Further study is needed to investigate
these matters.
Our study has several strengths. We utilized a nationwide
longitudinal database that covers the entire Korean popula-
tion. Hence, we captured nearly all patients who started
antihypertensive treatment, allowing a large sample size and
long follow-up despite strict identiﬁcation criteria. Because of
this large inception cohort design, detailed stratiﬁed analyses
by sociodemographic factors were also possible. Furthermore,
main exposure variables were derived from objective data
rather than from self-report. Especially, NHIS premium is
levied according to comprehensive assessment of income and
assets and is thus a reliable measure of household socioe-
conomic status. However, we acknowledge that our study also
has some limitations. First, the NHIS cohort is based on
secondary administrative data in which all medical informa-
tion had been collected by healthcare professionals but not
strictly controlled for research purposes. In this regard the
operational deﬁnitions of hypertension and CVD may be prone
to misdiagnoses and require further validations in future
studies. Nonetheless, diagnosis of hypertension using claims
has been well reviewed, and its agreement with medical
records has been reported.15,35 Generally accepted identiﬁ-
cation criteria include case exclusion for the previous
≥6 months and availability of data for ≥12 months following
index date with ≥2 prescriptions.15 We used similar standards
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but a longer window period—24 months before and
24 months following index date—to allow stricter case
deﬁnition and assessment of comorbidity. However, individ-
uals with high blood pressure but with no records of
healthcare utilization would not have been identiﬁed. Because
people with low income have lower rates of awareness and
treatment for hypertension,2-4 excess risk for mortality with
low income may have been underestimated in our study.
Second, the household income quintile may not equate to an
individual family member’s income or a sex-speciﬁc or within-
study income quintile. However, it is unlikely that this
measurement error would distort the income-mortality asso-
ciation observed in our study. Third, we arbitrarily chose the
ﬁrst 2 years of treatment for calculating medication adher-
ence. Although considering a longer period of time could
provide a more inclusive measure of medication adherence, it
may also be more prone to reverse causality or overestima-
tion of adherence.36 In a clinical setting, attainment of early
treatment compliance is often challenging. An Italian popu-
lation-based study reported almost 50% cumulative incidence
of discontinuation of antihypertensive medication at 2 years
after initiation.37 Association of early discontinuation with
cardiovascular events was also reported.38 Therefore, early-
treatment nonadherence would be a reasonable representa-
tion of high-risk behaviors associated with adverse outcome.
Fourth, lifestyle and some risk factors were not universally
available in our data. Thus, we performed additional analyses
on a subgroup with health examination results and found
similar results. However, information on sodium intake,
education level, or a distinction between self- and unemployed
individuals was not available. Therefore, some residual and
unmeasured confounding may exist. Finally, our study was
based on Korean adults under universal health insurance and
should be interpreted with caution when applied to different
populations or different healthcare systems.
In conclusion, both low household income and poor
medication adherence are associated with higher risk for
death and CVD hospitalization in individuals newly treated for
hypertension, but those with low income are subject to
greater increase of risk attributable to poor adherence.
Therefore, monitoring adherence is crucial when treating
hypertension in low-income patients, and policies should
focus on promoting medication adherence in populations of
low socioeconomic status.
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Table S1. Index drug codes. 
Drug class ATC code* 
Diuretics C03A, C03B, C03C, C03D, C03E 
Beta-blockers C07 
Calcium channel blockers C08 
ACE inhibitors C09A, C09B 
Angiotensin II receptor blockers C09C, C09D 
Others C02A, C02C, C02D, C02L 
*Including subcodes.
ACE, angiotensin-converting-enzyme; ATC, Anatomical Therapeutic Chemical classification.
Table S2. Hospital diagnosis codes. 
Diagnosis ICD-10 code* 
Primary hypertension I10 and antihypertensive medication 
Any hypertensive disease (for exclusion) I10-I13, I15 or antihypertensive medication 
Myocardial infarction I21-I23 
Heart failure I50 
Stroke I60-I64 
Cardiovascular death I00-I99 
*Including subcodes.
ICD-10, International Classification of Disease, 10th edition.
 Table S3. Baseline characteristics by medication adherence. 
Medication adherence 
Variables Good Moderate Poor 
(N=742,387) (N=348,236) (N=560,941) 
Age, yr 55 [47-63] 53 [46-63] 52 [44-62] 
Sex 
   Female 353,384 (47.6%) 167,682 (48.2%) 263,433 (47.0%) 
   Male 389,003 (52.4%) 180,554 (51.8%) 297,508 (53.0%) 
Household income, quintile 
   5, highest 225,169 (30.3%) 97,682 (28.1%) 147,758 (26.3%) 
   4 167,883 (22.6%) 78,119 (22.4%) 125,432 (22.4%) 
   3 128,731 (17.3%) 63,202 (18.1%) 105,541 (18.8%) 
   2 101,928 (13.7%) 51,511 (14.8%) 87,174 (15.5%) 
   1, lowest 118,676 (16.0%) 57,722 (16.6%) 95,036 (16.9%) 
Employment status 
   Employed workers 178,942 (24.1%) 77,744 (22.3%) 119,293 (21.3%) 
   Self- or non-employed 563,445 (75.9%) 270,492 (77.7%) 441,648 (78.7%) 
Initial antihypertensive agent* 
   Diuretics 201,016 (27.1%) 96,758 (27.8%) 161,013 (28.7%) 
   Beta-blockers 152,823 (20.6%) 75,183 (21.6%) 136,563 (24.3%) 
   Calcium channel blockers 459,464 (61.9%) 205,924 (59.1%) 296,823 (52.9%) 
   ACE inhibitors 95,696 (12.9%) 46,386 (13.3%) 67,046 (12.0%) 
   ARBs 173,857 (23.4%) 74,762 (21.5%) 100,376 (17.9%) 
   Others 3,104 (0.4%) 2,093 (0.6%) 6,467 (1.2%) 
Number of drug classes 
   1 465,491 (62.7%) 224,131 (64.4%) 389,497 (69.4%) 
   2 217,481 (29.3%) 98,464 (28.3%) 139,433 (24.9%) 
   ≥3 59,415 (8.0%) 25,641 (7.4%) 32,011 (5.7%) 
Use of glucose-lowering drugs 130,753 (17.6%) 67,687 (19.4%) 88,513 (15.8%) 
Use of lipid-lowering drugs 97,451 (13.1%) 43,893 (12.6%) 66,174 (11.8%) 
Charlson Comorbidity Index 
   0 394,445 (53.1%) 175,640 (50.4%) 265,687 (47.4%) 
   1 139,405 (18.8%) 67,814 (19.5%) 107,993 (19.3%) 
   2 119,432 (16.1%) 57,726 (16.6%) 100,925 (18.0%) 
   ≥3 89,105 (12.0%) 47,056 (13.5%) 86,336 (15.4%) 
Medication possession ratio 0.95 [0.89-1.00] 0.67 [0.59-0.74] 0.16 [0.06-0.33] 
*Counted with duplicates for combination therapy.
Data are presented as median [interquartile range] or frequency (percent). ACE, angiotensin-
converting-enzyme; ARB, angiotensin II receptor blocker.
 Table S4. Hospitalizations for ASCVD and heart failure according to household income and medication adherence. 
- ASCVD (MI and/or stroke) - Heart failure
Variables Persons Events Rate* HR (99% CI) Events Rate* HR (99% CI)
Model 1 Model 2 Model 1 Model 2
Total 1,651,564 78,701 501.0 
  
8,736 54.8 
  
Income, quintile
5, highest 470,609 20,760 461.7 1.00 (reference) 1.00 (reference) 2,335 51.2 1.00 (reference) 1.00 (reference)
4 371,434 17,152 484.1 1.11 (1.08-1.14) 1.09 (1.07-1.12) 1,871 52.1 1.15 (1.06-1.25) 1.14 (1.05-1.23)
3 297,474 14,184 501.3 1.21 (1.17-1.24) 1.17 (1.14-1.20) 1,483 51.7 1.25 (1.15-1.36) 1.22 (1.12-1.33)
2 240,613 12,158 533.3 1.30 (1.26-1.34) 1.25 (1.21-1.28) 1,331 57.5 1.40 (1.28-1.53) 1.35 (1.24-1.48)
1, lowest 271,434 14,447 564.5 1.36 (1.32-1.40) 1.30 (1.26-1.33) 1,716 66.0 1.48 (1.36-1.61) 1.43 (1.32-1.56)
Adherence
Good 742,387 28,519 399.2 1.00 (reference) 1.00 (reference) 3,171 43.9 1.00 (reference) 1.00 (reference)
Moderate 348,236 17,158 518.6 1.37 (1.33-1.40) 1.35 (1.32-1.39) 1,944 57.9 1.38 (1.28-1.49) 1.35 (1.25-1.46)
Poor 560,941 33,024 628.4 1.71 (1.67-1.74) 1.75 (1.71-1.79) 3,621 67.7 1.66 (1.56-1.77) 1.67 (1.57-1.78)
Men 867,065 46,456 568.9 3,767 45.4 
Income, quintile
5, highest 257,900 12,030 490.6 1.00 (reference) 1.00 (reference) 972 39.1 1.00 (reference) 1.00 (reference)
4 200,773 10,281 541.5 1.14 (1.10-1.18) 1.11 (1.08-1.15) 816 42.3 1.15 (1.02-1.30) 1.13 (1.00-1.28)
3 159,625 8,710 579.5 1.25 (1.20-1.29) 1.20 (1.16-1.25) 687 44.9 1.30 (1.14-1.47) 1.26 (1.10-1.43)
2 122,993 7,398 644.4 1.37 (1.32-1.42) 1.30 (1.26-1.36) 589 50.3 1.45 (1.26-1.66) 1.39 (1.21-1.59)
1, lowest 125,774 8,037 689.9 1.43 (1.38-1.49) 1.35 (1.30-1.41) 703 59.1 1.63 (1.43-1.85) 1.56 (1.37-1.77)
Adherence
Good 389,003 16,776 451.3 1.00 (reference) 1.00 (reference) 1,327 35.2 1.00 (reference) 1.00 (reference)
Moderate 180,554 9,863 580.2 1.36 (1.32-1.41) 1.34 (1.30-1.39) 800 46.3 1.42 (1.27-1.60) 1.39 (1.24-1.56)
Poor 297,508 19,817 720.7 1.73 (1.68-1.77) 1.77 (1.72-1.81) 1,640 58.4 1.82 (1.65-2.00) 1.83 (1.66-2.01)
Women 784,499 32,245 427.6 4,969 65.1 
Income, quintile
5, highest 212,709 8,730 427.0 1.00 (reference) 1.00 (reference) 1,363 65.9 1.00 (reference) 1.00 (reference)
4 170,661 6,871 417.9 1.09 (1.05-1.14) 1.08 (1.03-1.12) 1,055 63.4 1.16 (1.05-1.29) 1.15 (1.03-1.28)
3 137,849 5,474 412.7 1.17 (1.12-1.22) 1.14 (1.09-1.19) 796 59.3 1.22 (1.09-1.37) 1.20 (1.07-1.34)
2 117,620 4,760 420.6 1.23 (1.17-1.29) 1.18 (1.13-1.24) 742 64.8 1.37 (1.22-1.54) 1.33 (1.18-1.50)
1, lowest 145,660 6,410 459.7 1.31 (1.25-1.37) 1.26 (1.20-1.31) 1,013 71.7 1.41 (1.27-1.58) 1.37 (1.23-1.53)
Adherence
Good 353,384 11,743 342.7 1.00 (reference) 1.00 (reference) 1,844 53.3 1.00 (reference) 1.00 (reference)
Moderate 167,682 7,295 453.4 1.36 (1.31-1.41) 1.35 (1.30-1.40) 1,144 70.2 1.33 (1.21-1.47) 1.31 (1.19-1.44)
Poor 263,433 13,207 527.2 1.66 (1.60-1.71) 1.70 (1.65-1.76) 1,981 77.9 1.54 (1.42-1.68) 1.54 (1.41-1.67)
Model 1 was adjusted for age, sex, and employment status. 
Model 2 was further adjusted for household income, Charlson Comorbidity Index, use of glucose-lowering drugs, use of lipid-lowering drugs, 
antihypertensive drug class, and medication adherence. 
*Rate per 100,000 person-years. ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.
 Table S5. Hospitalizations for myocardial infarction and stroke according to household income and medication adherence. 
- Myocardial infarction - Stroke
Variables Persons Events Rate* HR (99% CI) Events Rate* HR (99% CI)
Model 1 Model 2 Model 1 Model 2
Total 1,651,564 15,811 99.4 
  
64,098 406.8 
  
Income, quintile
5, highest 470,609 4,260 93.7 1.00 (reference) 1.00 (reference) 16,810 372.8 1.00 (reference) 1.00 (reference)
4 371,434 3,494 97.4 1.09 (1.03-1.16) 1.09 (1.02-1.15) 13,911 391.5 1.12 (1.09-1.15) 1.10 (1.06-1.13)
3 297,474 2,935 102.4 1.19 (1.11-1.26) 1.17 (1.10-1.24) 11,479 404.5 1.22 (1.18-1.25) 1.17 (1.14-1.21)
2 240,613 2,394 103.6 1.22 (1.14-1.30) 1.19 (1.12-1.27) 9,942 434.8 1.32 (1.28-1.37) 1.26 (1.22-1.30)
1, lowest 271,434 2,728 105.1 1.24 (1.16-1.32) 1.20 (1.13-1.28) 11,956 465.7 1.40 (1.35-1.44) 1.32 (1.28-1.37)
Adherence
Good 742,387 6,363 88.2 1.00 (reference) 1.00 (reference) 22,583 315.2 1.00 (reference) 1.00 (reference)
Moderate 348,236 3,528 105.3 1.25 (1.19-1.32) 1.24 (1.17-1.31) 13,880 418.2 1.39 (1.35-1.43) 1.38 (1.34-1.42)
Poor 560,941 5,920 110.8 1.35 (1.29-1.41) 1.39 (1.33-1.46) 27,635 524.2 1.80 (1.76-1.84) 1.84 (1.80-1.89)
Men 867,065 11,171 134.9 36,092 440.1 
Income, quintile
5, highest 257,900 3,055 123.2 1.00 (reference) 1.00 (reference) 9,191 373.4 1.00 (reference) 1.00 (reference)
4 200,773 2,478 128.8 1.07 (0.99-1.14) 1.06 (0.99-1.14) 7,967 417.9 1.15 (1.11-1.20) 1.13 (1.08-1.17)
3 159,625 2,124 139.4 1.17 (1.08-1.25) 1.15 (1.07-1.24) 6,749 447.1 1.27 (1.22-1.33) 1.22 (1.17-1.27)
2 122,993 1,675 143.6 1.19 (1.10-1.29) 1.17 (1.08-1.26) 5,835 506.0 1.43 (1.37-1.49) 1.35 (1.29-1.41)
1, lowest 125,774 1,839 155.3 1.26 (1.17-1.36) 1.23 (1.14-1.33) 6,350 542.4 1.50 (1.43-1.56) 1.40 (1.34-1.46)
Adherence
Good 389,003 4,545 121.0 1.00 (reference) 1.00 (reference) 12,500 335.0 1.00 (reference) 1.00 (reference)
Moderate 180,554 2,446 141.9 1.22 (1.14-1.30) 1.20 (1.13-1.28) 7,596 444.9 1.41 (1.36-1.47) 1.39 (1.34-1.45)
Poor 297,508 4,180 149.3 1.31 (1.24-1.38) 1.34 (1.27-1.42) 15,996 579.1 1.87 (1.82-1.93) 1.91 (1.85-1.97)
Women 784,499 4,640 60.8 28,006 370.8 
Income, quintile
5, highest 212,709 1,205 58.3 1.00 (reference) 1.00 (reference) 7,619 372.0 1.00 (reference) 1.00 (reference)
4 170,661 1,016 61.1 1.19 (1.07-1.33) 1.18 (1.06-1.32) 5,944 360.9 1.08 (1.03-1.13) 1.06 (1.02-1.11)
3 137,849 811 60.5 1.28 (1.14-1.45) 1.26 (1.12-1.42) 4,730 356.0 1.15 (1.10-1.21) 1.12 (1.07-1.18)
2 117,620 719 62.8 1.38 (1.22-1.56) 1.34 (1.19-1.52) 4,107 362.3 1.21 (1.15-1.27) 1.16 (1.11-1.22)
1, lowest 145,660 889 63.0 1.33 (1.19-1.49) 1.30 (1.16-1.46) 5,606 401.3 1.31 (1.25-1.37) 1.25 (1.20-1.31)
Adherence
Good 353,384 1,818 52.6 1.00 (reference) 1.00 (reference) 10,083 293.8 1.00 (reference) 1.00 (reference)
Moderate 167,682 1,082 66.4 1.29 (1.17-1.43) 1.28 (1.16-1.42) 6,284 389.9 1.36 (1.30-1.42) 1.35 (1.29-1.41)
Poor 263,433 1,740 68.4 1.40 (1.28-1.52) 1.45 (1.33-1.58) 11,639 463.7 1.70 (1.64-1.76) 1.74 (1.68-1.80)
Model 1 was adjusted for age, sex, and employment status. 
Model 2 was further adjusted for household income, Charlson Comorbidity Index, use of glucose-lowering drugs, use of lipid-lowering drugs, 
antihypertensive drug class, and medication adherence. 
*Rate per 100,000 person-years. CI, confidence interval; HR, hazard ratio.
 Table S6. All-cause and cardiovascular death according to household income and medication adherence in health examinees. 
- All-cause death - Cardiovascular death
Variables Persons Events Rate* HR (99% CI) 
 
Events Rate* HR (99% CI) 
Model 1 Model 2 Model 1 Model 2 
Total 643,026 42,918 685.3 7,825 124.9 
Income, quintile 
  5, highest 197,745 11,301 584.5 1.00 (reference) 1.00 (reference) 2,023 104.6 1.00 (reference) 1.00 (reference) 
  4 146,368 9,108 637.6 1.18 (1.14-1.22) 1.14 (1.10-1.18) 1,661 116.3 1.22 (1.12-1.33) 1.17 (1.07-1.27) 
  3 109,060 7,401 697.3 1.30 (1.25-1.35) 1.23 (1.18-1.27) 1,343 126.5 1.33 (1.22-1.46) 1.25 (1.14-1.37) 
  2 85,692 6,698 806.5 1.43 (1.38-1.49) 1.33 (1.27-1.38) 1,227 147.7 1.46 (1.33-1.60) 1.34 (1.22-1.48) 
  1, lowest 104,161 8,410 833.6 1.47 (1.41-1.52) 1.36 (1.31-1.41) 1,571 155.7 1.50 (1.37-1.64) 1.37 (1.26-1.50) 
Adherence 
  Good 308,232 16,835 557.4 1.00 (reference) 1.00 (reference) 2,877 95.2 1.00 (reference) 1.00 (reference) 
  Moderate 132,247 9,010 700.1 1.29 (1.24-1.33) 1.25 (1.21-1.29) 1,703 132.3 1.44 (1.33-1.56) 1.40 (1.30-1.52) 
  Poor 202,547 17,073 873.1 1.57 (1.53-1.62) 1.50 (1.45-1.54) 3,245 165.9 1.81 (1.70-1.94) 1.75 (1.64-1.88) 
Income and Adherence 
  5, highest Good 99,188 4,747 487.2 1.00 (reference) 1.00 (reference) 820 84.2 1.00 (reference) 1.00 (reference)  
Moderate 40,270 2,392 608.5 1.31 (1.23-1.40) 1.27 (1.19-1.36) 427 108.6 1.38 (1.18-1.61) 1.34 (1.15-1.56) 
Poor 58,287 4,162 735.3 1.51 (1.43-1.60) 1.45 (1.37-1.53) 776 137.1 1.69 (1.48-1.92) 1.64 (1.44-1.87) 
  4 Good 69,541 3,643 534.1 1.18 (1.11-1.25) 1.14 (1.08-1.21) 622 91.2 1.18 (1.03-1.36) 1.14 (0.99-1.31) 
Moderate 29,922 1,863 638.3 1.48 (1.38-1.59) 1.40 (1.30-1.50) 364 124.7 1.73 (1.47-2.03) 1.63 (1.38-1.91) 
Poor 46,905 3,602 792.4 1.82 (1.72-1.93) 1.67 (1.58-1.77) 675 148.5 2.09 (1.82-2.39) 1.94 (1.69-2.22) 
  3 Good 49,969 2,692 549.7 1.22 (1.15-1.30) 1.16 (1.09-1.23) 459 93.7 1.22 (1.05-1.42) 1.15 (0.99-1.34) 
Moderate 22,631 1,571 714.0 1.66 (1.54-1.78) 1.52 (1.41-1.64) 301 136.8 1.90 (1.59-2.26) 1.73 (1.45-2.06) 
Poor 36,460 3,138 892.4 2.10 (1.98-2.23) 1.90 (1.78-2.01) 583 165.8 2.39 (2.08-2.76) 2.17 (1.89-2.50) 
  2 Good 39,344 2,445 636.1 1.41 (1.33-1.51) 1.31 (1.23-1.40) 401 104.3 1.35 (1.15-1.58) 1.24 (1.06-1.45) 
Moderate 17,886 1,474 851.4 1.87 (1.73-2.02) 1.70 (1.57-1.83) 281 162.3 2.08 (1.74-2.49) 1.88 (1.57-2.25) 
Poor 28,462 2,779 1017.9 2.20 (2.07-2.34) 1.94 (1.82-2.06) 545 199.6 2.60 (2.25-3.00) 2.31 (2.00-2.67) 
  1, lowest Good 50,190 3,308 675.3 1.47 (1.38-1.56) 1.37 (1.29-1.45) 575 117.4 1.46 (1.26-1.68) 1.34 (1.16-1.55)  
Moderate 21,538 1,710 819.1 1.78 (1.65-1.91) 1.60 (1.49-1.72) 330 158.1 1.96 (1.65-2.32) 1.75 (1.48-2.08) 
Poor 32,433 3,392 1093.6 2.31 (2.18-2.45) 2.04 (1.92-2.16) 666 214.7 2.68 (2.34-3.07) 2.38 (2.07-2.72) 
Model 1 was adjusted for age, sex, employment status, household income, Charlson Comorbidity Index, use of glucose-lowering drugs, use of lipid-
lowering drugs, antihypertensive drug class, and medication adherence. 
Model 2 was further adjusted for cigarette smoking, alcohol consumption, physical exercise, body mass index, systolic blood pressure, fasting 
glucose, and total cholesterol. 
*Rate per 100,000 person-years. CI, confidence interval; HR, hazard ratio.
 Table S7. Hospitalizations for ASCVD and heart failure according to household income and medication adherence in health examinees. 
- ASCVD (MI and/or stroke) - Heart failure 
Variables Persons Events Rate* HR (99% CI) Events Rate* HR (99% CI) 
Model 1 Model 2 Model 1 Model 2 
Total 643,026 26,934 436.1 2,696 43.1 
Income, quintile 
  5, highest 197,745 7,604 398.4 1.00 (reference) 1.00 (reference) 702 36.3 1.00 (reference) 1.00 (reference) 
  4 146,368 5,922 420.2 1.10 (1.05-1.15) 1.06 (1.02-1.11) 541 37.9 1.14 (0.98-1.32) 1.11 (0.96-1.29) 
  3 109,060 4,651 444.5 1.15 (1.10-1.21) 1.10 (1.05-1.15) 503 47.4 1.44 (1.24-1.67) 1.39 (1.20-1.62) 
  2 85,692 3,916 478.7 1.21 (1.15-1.27) 1.14 (1.08-1.20) 412 49.7 1.40 (1.20-1.65) 1.35 (1.15-1.59) 
  1, lowest 104,161 4,841 487.4 1.22 (1.16-1.28) 1.15 (1.09-1.20) 538 53.4 1.46 (1.26-1.71) 1.41 (1.21-1.64) 
Adherence 
  Good 308,232 10,675 357.5 1.00 (reference) 1.00 (reference) 1,014 33.6 1.00 (reference) 1.00 (reference) 
  Moderate 132,247 5,792 456.8 1.33 (1.27-1.38) 1.31 (1.25-1.37) 602 46.8 1.40 (1.22-1.60) 1.37 (1.20-1.57) 
  Poor 202,547 10,467 544.7 1.64 (1.58-1.70) 1.63 (1.57-1.69) 1,080 55.3 1.65 (1.47-1.85) 1.59 (1.42-1.79) 
Income and Adherence 
  5, highest Good 99,188 3,214 333.4 1.00 (reference) 1.00 (reference) 295 30.3 1.00 (reference) 1.00 (reference)  
Moderate 40,270 1,621 418.0 1.32 (1.22-1.43) 1.30 (1.20-1.41) 149 37.9 1.29 (1.00-1.68) 1.27 (0.98-1.64) 
Poor 58,287 2,769 497.2 1.59 (1.49-1.70) 1.59 (1.49-1.71) 258 45.6 1.50 (1.20-1.87) 1.44 (1.16-1.80) 
  4 Good 69,541 2,362 350.2 1.09 (1.02-1.17) 1.06 (0.99-1.14) 198 29.1 1.04 (0.82-1.31) 1.01 (0.80-1.29) 
Moderate 29,922 1,240 430.9 1.42 (1.30-1.55) 1.36 (1.25-1.48) 119 40.8 1.51 (1.14-1.99) 1.45 (1.09-1.92) 
Poor 46,905 2,320 518.9 1.79 (1.66-1.92) 1.72 (1.61-1.85) 224 49.3 1.85 (1.47-2.33) 1.74 (1.38-2.19) 
  3 Good 49,969 1,720 355.2 1.10 (1.02-1.19) 1.06 (0.98-1.14) 181 37.0 1.33 (1.04-1.70) 1.29 (1.01-1.65) 
Moderate 22,631 1,006 464.2 1.52 (1.38-1.67) 1.43 (1.30-1.57) 121 55.1 2.05 (1.55-2.70) 1.95 (1.47-2.57) 
Poor 36,460 1,925 557.2 1.93 (1.79-2.08) 1.83 (1.70-1.97) 201 57.2 2.21 (1.74-2.80) 2.06 (1.62-2.61) 
  2 Good 39,344 1,465 385.8 1.20 (1.11-1.30) 1.14 (1.05-1.23) 156 40.6 1.44 (1.11-1.85) 1.38 (1.07-1.79) 
Moderate 17,886 872 512.0 1.61 (1.46-1.77) 1.50 (1.36-1.65) 82 47.4 1.61 (1.17-2.22) 1.52 (1.10-2.10) 
Poor 28,462 1,579 589.1 1.93 (1.79-2.09) 1.82 (1.68-1.97) 174 63.8 2.21 (1.73-2.84) 2.05 (1.60-2.63) 
  1, lowest Good 50,190 1,914 395.7 1.21 (1.12-1.31) 1.14 (1.06-1.23) 184 37.6 1.28 (1.00-1.64) 1.23 (0.96-1.57)  
Moderate 21,538 1,053 512.6 1.59 (1.45-1.75) 1.48 (1.35-1.62) 131 62.9 2.07 (1.57-2.71) 1.95 (1.48-2.56) 
Poor 32,433 1,874 616.4 1.98 (1.83-2.13) 1.85 (1.72-2.00) 223 72.0 2.36 (1.87-2.98) 2.19 (1.74-2.77) 
Model 1 was adjusted for age, sex, employment status, household income, Charlson Comorbidity Index, use of glucose-lowering drugs, use of lipid-
lowering drugs, antihypertensive drug class, and medication adherence. 
Model 2 was further adjusted for cigarette smoking, alcohol consumption, physical exercise, body mass index, systolic blood pressure, fasting 
glucose, and total cholesterol. 
*Rate per 100,000 person-years. ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.
 Figure S1. Flowchart of inclusion and exclusion criteria.
Age 30 to 80
claimed for I10 and 
antihypertensive medication 
2004.1.1 - 2007.12.31
N=6,467,000
Newly treated hypertension
2004.1.1 - 2007.12.31
N=1,977,432
Final study population
N=1,651,564
Claimed for I10-13, I15 or 
antihypertensive medication 
in 2002 or 2003
N=3,628,834
Less than 2 prescriptions
during the first year
N=575,699
Claimed for MI, HF, or stroke 
before index date
N=285,035
Died or had CVD event
within 2 years after index date
N=88,830
Household income 
unavailable or enrolled in 
Medical Aid
N=237,038
 P for interaction between income and adherence in men and women were 0.305 and 0.002 for ASCVD and 0.100 and 0.520 for 
heart failure. *Rate per 100,000 person-years. ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; HR, 
hazard ratio.
Men ASCVD (MI and/or stroke) Heart failure
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 126,148 4,797 395.7 1.00 (reference) 383 31.2 1.00 (reference)
Moderate 53,094 2,592 514.2 1.36 (1.28-1.45) 211 41.2 1.40 (1.12-1.74)
Poor 78,658 4,641 631.0 1.71 (1.62-1.81) 378 50.4 1.69 (1.40-2.04)
4 Good 90,474 3,772 435.4 1.10 (1.04-1.17) 287 32.7 1.08 (0.88-1.32)
Moderate 41,733 2,152 545.6 1.47 (1.37-1.57) 175 43.7 1.55 (1.22-1.96)
Poor 68,566 4,357 683.0 1.96 (1.86-2.07) 354 54.4 2.03 (1.68-2.46)
3 Good 67,773 2,969 458.4 1.18 (1.11-1.25) 237 36.1 1.24 (1.00-1.54)
Moderate 33,791 1,871 588.4 1.61 (1.50-1.73) 158 48.8 1.82 (1.43-2.33)
Poor 58,061 3,870 720.2 2.12 (2.00-2.24) 292 53.2 2.12 (1.73-2.59)
2 Good 50,833 2,457 508.7 1.29 (1.21-1.37) 196 40.0 1.37 (1.09-1.72)
Moderate 25,825 1,565 648.6 1.72 (1.60-1.85) 122 49.6 1.81 (1.38-2.37)
Poor 46,335 3,376 796.6 2.30 (2.17-2.44) 271 62.5 2.47 (2.01-3.04)
1, lowest Good 53,775 2,781 547.6 1.35 (1.27-1.43) 224 43.4 1.43 (1.15-1.78)
Moderate 26,111 1,683 695.2 1.78 (1.65-1.91) 134 54.2 1.86 (1.44-2.42)
Poor 45,888 3,573 860.9 2.38 (2.25-2.52) 345 81.1 3.02 (2.49-3.67)
Women ASCVD (MI and/or stroke) Heart failure
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 99,021 3,422 356.8 1.00 (reference) 570 58.9 1.00 (reference)
Moderate 44,588 1,972 461.1 1.33 (1.24-1.43) 286 66.0 1.13 (0.94-1.37)
Poor 69,100 3,336 507.0 1.59 (1.49-1.69) 507 76.0 1.39 (1.18-1.62)
4 Good 77,409 2,546 338.5 1.05 (0.98-1.12) 379 49.9 1.02 (0.86-1.21)
Moderate 36,386 1,541 440.8 1.40 (1.30-1.52) 231 65.3 1.34 (1.10-1.64)
Poor 56,866 2,784 513.1 1.78 (1.67-1.90) 445 80.9 1.76 (1.50-2.08)
3 Good 60,958 1,970 333.1 1.10 (1.02-1.18) 286 47.9 1.08 (0.90-1.31)
Moderate 29,411 1,202 425.1 1.45 (1.33-1.58) 189 66.1 1.52 (1.22-1.89)
Poor 47,480 2,302 509.2 1.91 (1.78-2.05) 321 70.0 1.72 (1.44-2.06)
2 Good 51,095 1,606 323.7 1.12 (1.03-1.21) 268 53.6 1.27 (1.05-1.54)
Moderate 25,686 1,113 451.4 1.56 (1.43-1.70) 174 69.7 1.61 (1.29-2.01)
Poor 40,839 2,041 524.7 1.99 (1.85-2.14) 300 76.0 1.89 (1.57-2.27)
1, lowest Good 64,901 2,199 349.9 1.20 (1.11-1.29) 341 53.7 1.22 (1.02-1.46)
Moderate 31,611 1,467 485.4 1.64 (1.51-1.77) 264 86.3 1.86 (1.54-2.26)
Poor 49,148 2,744 591.7 2.12 (1.98-2.27) 408 86.6 1.92 (1.62-2.27)
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Figure S2. Combined effect of household income and medication adherence on hospitalizations for ASCVD and heart failure in men and women. 
 P for interaction between income and adherence in men and women were 0.093 and 0.459 for myocardial infarction and 0.116 
and 0.001 for stroke. *Rate per 100,000 person-years. CI, confidence interval; HR, hazard ratio.
Men Myocardial infarction Stroke
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 126,148 1,357 110.9 1.00 (reference) 3,513 288.7 1.00 (reference)
Moderate 53,094 671 131.5 1.22 (1.08-1.38) 1,970 389.2 1.42 (1.32-1.53)
Poor 78,658 1,027 137.5 1.32 (1.18-1.47) 3,708 502.0 1.87 (1.76-1.98)
4 Good 90,474 980 112.0 1.02 (0.91-1.13) 2,846 327.3 1.13 (1.06-1.21)
Moderate 41,733 501 125.4 1.18 (1.03-1.35) 1,678 423.8 1.57 (1.45-1.69)
Poor 68,566 997 153.7 1.54 (1.38-1.72) 3,443 537.2 2.12 (1.99-2.25)
3 Good 67,773 825 126.1 1.15 (1.03-1.29) 2,201 338.5 1.19 (1.11-1.28)
Moderate 33,791 488 151.4 1.43 (1.25-1.64) 1,426 446.4 1.69 (1.56-1.83)
Poor 58,061 811 148.2 1.50 (1.34-1.69) 3,122 578.3 2.35 (2.20-2.50)
2 Good 50,833 644 131.8 1.19 (1.05-1.34) 1,850 381.4 1.33 (1.23-1.43)
Moderate 25,825 379 154.6 1.43 (1.23-1.66) 1,208 498.4 1.83 (1.67-1.99)
Poor 46,335 652 150.8 1.51 (1.34-1.71) 2,777 652.2 2.60 (2.44-2.78)
1, lowest Good 53,775 739 143.7 1.26 (1.12-1.42) 2,090 409.7 1.39 (1.29-1.49)
Moderate 26,111 407 165.4 1.48 (1.28-1.72) 1,314 539.9 1.90 (1.75-2.07)
Poor 45,888 693 163.4 1.58 (1.40-1.78) 2,946 706.1 2.70 (2.53-2.88)
Women Myocardial infarction Stroke
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 99,021 522 53.9 1.00 (reference) 2,946 306.7 1.00 (reference)
Moderate 44,588 250 57.7 1.10 (0.91-1.35) 1,734 404.8 1.36 (1.26-1.47)
Poor 69,100 433 64.9 1.36 (1.15-1.61) 2,939 445.9 1.62 (1.52-1.73)
4 Good 77,409 386 50.9 1.06 (0.89-1.26) 2,199 292.0 1.05 (0.97-1.13)
Moderate 36,386 256 72.4 1.55 (1.27-1.89) 1,300 371.0 1.37 (1.26-1.49)
Poor 56,866 374 68.0 1.61 (1.35-1.92) 2,445 449.8 1.81 (1.68-1.94)
3 Good 60,958 314 52.6 1.18 (0.98-1.42) 1,680 283.6 1.09 (1.00-1.18)
Moderate 29,411 191 66.8 1.56 (1.25-1.94) 1,024 361.4 1.43 (1.30-1.57)
Poor 47,480 306 66.7 1.72 (1.42-2.07) 2,026 447.3 1.94 (1.80-2.09)
2 Good 51,095 269 53.8 1.27 (1.05-1.54) 1,358 273.4 1.09 (1.00-1.19)
Moderate 25,686 174 69.7 1.64 (1.31-2.06) 950 384.6 1.54 (1.40-1.69)
Poor 40,839 276 69.9 1.82 (1.50-2.21) 1,799 461.7 2.02 (1.87-2.19)
1, lowest Good 64,901 327 51.5 1.20 (1.00-1.44) 1,900 301.9 1.20 (1.11-1.29)
Moderate 31,611 211 68.9 1.57 (1.27-1.94) 1,276 421.4 1.65 (1.51-1.79)
Poor 49,148 351 74.5 1.82 (1.52-2.17) 2,430 523.0 2.17 (2.02-2.33)
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Figure S3. Combined effect of household income and medication adherence on hospitalizations for myocardial infarction and stroke in men and women. 
 P for interaction between income and adherence in men and women were 0.045 and 0.207 for all-cause death and 0.086 and 
0.972 for cardiovascular death. *Rate per 100,000 person-years. CI, confidence interval; HR, hazard ratio.
Men All-cause death Cardiovascular death
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 71,927 4,727 674.5 1.00 (reference) 667 95.2 1.00 (reference)
Moderate 30,898 2,459 823.3 1.28 (1.17-1.42) 396 132.6 1.40 (1.11-1.75)
Poor 46,348 4,807 1086.3 1.61 (1.48-1.75) 799 180.6 1.81 (1.49-2.19)
4 Good 50,421 3,668 748.5 1.16 (1.07-1.26) 564 115.1 1.19 (0.98-1.44)
Moderate 23,747 2,136 934.3 1.52 (1.37-1.68) 354 154.8 1.92 (1.54-2.40)
Poor 39,634 4,446 1178.3 2.00 (1.84-2.17) 768 203.5 2.28 (1.89-2.76)
3 Good 36,882 2,780 776.6 1.24 (1.14-1.36) 437 122.1 1.26 (1.02-1.55)
Moderate 18,918 1,784 981.8 1.71 (1.54-1.90) 273 150.2 1.77 (1.38-2.26)
Poor 33,162 3,996 1271.1 2.14 (1.96-2.33) 665 211.5 2.70 (2.22-3.28)
2 Good 27,662 2,423 905.7 1.47 (1.34-1.61) 386 144.3 1.49 (1.19-1.85)
Moderate 14,118 1,562 1158.1 1.87 (1.68-2.09) 270 200.2 2.10 (1.63-2.70)
Poor 26,071 3,652 1492.4 2.50 (2.29-2.73) 680 277.9 2.92 (2.39-3.57)
1, lowest Good 29,691 2,982 1044.6 1.54 (1.41-1.69) 494 173.1 1.49 (1.20-1.84)
Moderate 14,450 1,710 1244.5 2.00 (1.80-2.23) 268 195.0 1.94 (1.50-2.51)
Poor 25,985 4,099 1696.4 2.79 (2.56-3.03) 749 310.0 3.30 (2.72-4.01)
Women All-cause death Cardiovascular death
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 56,099 3,097 563.4 1.00 (reference) 653 118.8 1.00 (reference)
Moderate 25,097 1,813 742.9 1.19 (1.05-1.34) 439 179.9 1.17 (0.91-1.49)
Poor 38,581 3,174 851.1 1.52 (1.37-1.69) 725 194.4 1.64 (1.33-2.01)
4 Good 42,908 2,103 499.0 1.05 (0.94-1.17) 405 96.1 0.96 (0.77-1.21)
Moderate 20,025 1,293 662.4 1.48 (1.30-1.68) 277 141.9 1.63 (1.27-2.09)
Poor 31,590 2,363 771.9 1.65 (1.47-1.84) 581 189.8 1.91 (1.53-2.37)
3 Good 33,455 1,639 499.4 1.16 (1.03-1.31) 328 99.9 1.15 (0.91-1.47)
Moderate 15,933 926 595.9 1.40 (1.21-1.62) 194 124.8 1.69 (1.28-2.23)
Poor 26,142 1,936 765.2 1.90 (1.68-2.14) 475 187.7 2.09 (1.66-2.65)
2 Good 27,865 1,333 487.2 1.19 (1.05-1.35) 294 107.5 1.18 (0.91-1.52)
Moderate 13,896 919 679.5 1.65 (1.43-1.91) 205 151.6 1.61 (1.20-2.16)
Poor 22,482 1,641 754.0 1.89 (1.67-2.14) 380 174.6 2.12 (1.67-2.71)
1, lowest Good 35,474 1,930 555.3 1.25 (1.11-1.40) 404 116.2 1.30 (1.04-1.63)
Moderate 17,036 1,183 714.9 1.69 (1.48-1.92) 263 158.9 1.77 (1.37-2.29)
Poor 27,167 2,358 902.9 2.06 (1.85-2.30) 601 230.1 2.18 (1.76-2.71)
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Figure S4. Combined effect of household income and medication adherence on all-cause and cardiovascular death in men and women who initiated monotherapy. 
 
Men All-cause death Cardiovascular death
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 46,574 3,299 729.1 1.00 (reference) 606 133.9 1.00 (reference)
Moderate 18,031 1,639 944.4 1.31 (1.21-1.42) 319 183.8 1.43 (1.20-1.71)
Poor 23,222 2,743 1244.8 1.60 (1.50-1.71) 535 242.8 1.77 (1.52-2.06)
4 Good 34,462 2,764 827.8 1.16 (1.08-1.24) 545 163.2 1.25 (1.07-1.45)
Moderate 14,938 1,457 1017.3 1.49 (1.37-1.61) 312 217.8 1.78 (1.49-2.13)
Poor 21,563 2,833 1391.1 1.99 (1.86-2.13) 585 287.2 2.33 (2.01-2.71)
3 Good 26,802 2,169 836.6 1.23 (1.14-1.32) 419 161.6 1.30 (1.10-1.53)
Moderate 12,414 1,277 1075.0 1.65 (1.52-1.80) 250 210.5 1.81 (1.49-2.20)
Poor 18,764 2,428 1373.0 2.13 (1.99-2.29) 509 287.8 2.55 (2.18-2.98)
2 Good 20,120 1,903 981.8 1.44 (1.33-1.55) 357 184.2 1.47 (1.23-1.74)
Moderate 9,803 1,174 1261.1 1.90 (1.74-2.07) 230 247.1 2.08 (1.71-2.55)
Poor 15,527 2,364 1630.4 2.51 (2.35-2.70) 506 349.0 3.05 (2.61-3.56)
1, lowest Good 20,852 2,191 1094.9 1.55 (1.44-1.66) 410 204.9 1.57 (1.33-1.86)
Moderate 9,848 1,353 1457.8 2.09 (1.92-2.27) 247 266.1 2.13 (1.75-2.59)
Poor 15,504 2,655 1852.3 2.75 (2.57-2.95) 581 405.3 3.41 (2.93-3.96)
Women All-cause death Cardiovascular death
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 34,551 2,084 617.2 1.00 (reference) 549 162.6 1.00 (reference)
Moderate 14,879 1,090 754.1 1.22 (1.11-1.34) 285 197.2 1.21 (1.00-1.46)
Poor 19,040 1,758 959.9 1.48 (1.36-1.61) 466 254.4 1.49 (1.26-1.75)
4 Good 28,053 1,511 549.3 1.07 (0.98-1.17) 364 132.3 1.01 (0.85-1.20)
Moderate 12,768 913 735.4 1.44 (1.30-1.60) 252 203.0 1.55 (1.28-1.89)
Poor 16,386 1,380 872.6 1.66 (1.52-1.82) 376 237.8 1.77 (1.49-2.11)
3 Good 22,507 1,179 535.1 1.16 (1.05-1.27) 283 128.4 1.09 (0.91-1.32)
Moderate 10,639 676 652.9 1.43 (1.28-1.60) 183 176.7 1.53 (1.23-1.91)
Poor 14,041 1,149 849.2 1.85 (1.68-2.03) 306 226.2 1.94 (1.61-2.33)
2 Good 19,013 1,019 547.5 1.24 (1.12-1.37) 236 126.8 1.14 (0.93-1.39)
Moderate 9,265 651 722.9 1.58 (1.41-1.78) 162 179.9 1.56 (1.24-1.97)
Poor 12,335 996 836.7 1.83 (1.66-2.03) 262 220.1 1.88 (1.55-2.29)
1, lowest Good 23,962 1,437 613.6 1.30 (1.19-1.42) 370 158.0 1.32 (1.11-1.57)
Moderate 11,520 923 827.9 1.66 (1.50-1.84) 257 230.5 1.81 (1.49-2.20)
Poor 15,062 1,518 1055.8 2.03 (1.86-2.22) 403 280.3 2.07 (1.75-2.45)
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P for interaction between income and adherence in men and women were 0.009 and 0.463 for all-cause death and 0.012 and 
0.694 for cardiovascular death. *Rate per 100,000 person-years. CI, confidence interval; HR, hazard ratio.
Figure S5. Combined effect of household income and medication adherence on all-cause and cardiovascular death in men and women who initiated combination therapy. 
 P for interaction between income and adherence in men and women were <0.001 and 0.194 for all-cause death and 0.030 and 
0.110 for cardiovascular death. *Rate per 100,000 person-years. CI, confidence interval; HR, hazard ratio.
Men All-cause death Cardiovascular death
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 126,153 8,530 694.8 1.00 (reference) 1,356 110.5 1.00 (reference)
Moderate 53,621 4,467 863.1 1.29 (1.23-1.35) 784 151.5 1.47 (1.31-1.65)
Poor 150,452 14,951 1037.9 1.54 (1.49-1.59) 2,600 180.5 1.80 (1.65-1.97)
4 Good 90,481 6,830 777.6 1.14 (1.09-1.19) 1,181 134.5 1.24 (1.12-1.38)
Moderate 42,086 3,906 965.4 1.50 (1.43-1.57) 716 177.0 1.79 (1.59-2.02)
Poor 131,136 14,292 1142.2 1.88 (1.81-1.95) 2,570 205.4 2.28 (2.09-2.49)
3 Good 67,777 5,261 800.9 1.23 (1.18-1.29) 911 138.7 1.35 (1.21-1.50)
Moderate 34,069 3,341 1022.9 1.68 (1.59-1.77) 570 174.5 1.87 (1.64-2.12)
Poor 110,889 12,750 1209.4 2.15 (2.07-2.23) 2,317 219.8 2.64 (2.41-2.88)
2 Good 50,840 4,614 940.0 1.45 (1.38-1.52) 785 159.9 1.55 (1.38-1.74)
Moderate 26,045 2,959 1191.8 1.92 (1.81-2.03) 541 217.9 2.27 (1.99-2.59)
Poor 88,194 11,650 1402.2 2.47 (2.38-2.56) 2,170 261.2 3.08 (2.81-3.37)
1, lowest Good 53,779 5,503 1065.2 1.59 (1.52-1.66) 958 185.4 1.74 (1.56-1.94)
Moderate 26,335 3,307 1324.9 2.03 (1.92-2.14) 560 224.4 2.21 (1.94-2.52)
Poor 86,108 12,900 1604.6 2.68 (2.59-2.78) 2,415 300.4 3.34 (3.06-3.65)
Women All-cause death Cardiovascular death
Income Adherence Persons Events Rate* HR (99% CI)    Low risk     High risk Events Rate* HR (99% CI)    Low risk     High risk
5, highest Good 99,023 5,597 577.3 1.00 (reference) 1,295 133.6 1.00 (reference)
Moderate 45,001 3,198 730.6 1.28 (1.21-1.36) 790 180.5 1.37 (1.22-1.54)
Poor 134,438 9,750 747.1 1.47 (1.41-1.54) 2,241 171.7 1.51 (1.38-1.65)
4 Good 77,411 3,900 513.1 1.07 (1.02-1.13) 843 110.9 1.04 (0.93-1.17)
Moderate 36,671 2,402 672.3 1.41 (1.33-1.50) 587 164.3 1.55 (1.36-1.76)
Poor 110,213 7,376 688.3 1.61 (1.54-1.69) 1,761 164.3 1.77 (1.61-1.94)
3 Good 60,964 3,040 508.6 1.18 (1.11-1.25) 654 109.4 1.14 (1.01-1.30)
Moderate 29,635 1,763 610.4 1.43 (1.34-1.54) 414 143.3 1.53 (1.32-1.77)
Poor 89,586 5,874 675.0 1.78 (1.69-1.87) 1,413 162.4 1.98 (1.79-2.19)
2 Good 51,096 2,552 509.2 1.23 (1.16-1.31) 571 113.9 1.24 (1.09-1.41)
Moderate 25,842 1,707 678.6 1.59 (1.48-1.71) 401 159.4 1.69 (1.46-1.96)
Poor 76,878 5,253 704.1 1.87 (1.78-1.96) 1,191 159.6 1.94 (1.75-2.16)
1, lowest Good 64,902 3,627 570.8 1.31 (1.24-1.38) 820 129.0 1.32 (1.18-1.49)
Moderate 31,827 2,316 749.9 1.63 (1.53-1.74) 563 182.3 1.76 (1.54-2.00)
Poor 91,883 7,410 836.3 1.98 (1.89-2.08) 1,849 208.7 2.22 (2.02-2.44)
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Figure S6. Combined effect of household income and medication adherence on all-cause and cardiovascular death in men and women who had ≥1 claim for antihypertensive medication. 
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Figure S7. Blood pressure change from baseline on follow-up according to medication 
adherence. Error bars represent 99% confidence intervals.
